AstraZeneca Pipeline Setback Affects Investor Sentiment

BMI View: The importance of maintaining healthy research and development (R&D) pipelines and launching new drugs by innovative drugmakers cannot be stressed enough. The patent cliff describes a period starting in 2009, peaking in 2011 and continuing through to 2013, when almost all the leading blockbusters will lose patent protection. This will result in a massive decline in sales for some of the world's largest drugmakers. BMI calculates that over the next five years, revenues of US$125bn from the top 10 products will be lost as a result. With regards to AstraZeneca - between 2010 and 2020 - Nexium, Crestor,

To read the full article, please choose one of the following options: